Mattias Carlsten

Om mig
Publikationer
CV
Populärvetenskap och samverkan

Om mig

Se sidan på engelska [1]
Tema: Att delta i forskning [2]
[1] http://ki.se/en/people/mattca
[2] http://ki.se/forskning/tema-att-delta-i-forskning

Artiklar

Article: GUT. 2025;74(7):1125-1136
Unlocking novel T cell-based immunotherapy for hepatocellular carcinoma through neoantigen-driven T cell receptor isolation
Maravelia P; Yao H; Cai C; Silva DN; Fransson J; Nilsson OB; Lu Y-CW; Micke P; Botling J; Gatto F; Rovesti G; Carlsten M; Sallberg M; Stal P; Jorns C; Buggert M; Pasetto A
Journal article: HEMASPHERE. 2025;9(6):e70160
Development of myeloid neoplasia associated with prolonged immune cell-associated hematotoxicity after CAR T-cell treatment of B-cell lymphoma: Should we surveille for pre-existing myeloid mutations?
Carlsten M; Lindfors Rossi EL; Jädersten M; Tesi B; Abd Own S; Sander B; Deneberg S; Ivinskiy A; Sonnevi K; Sjölund H; Enblad G; Wahlin B; Mielke S
Article: CURRENT PROTOCOLS. 2024;4(11):e70040
Optimizing CAR-NK Cell Transduction and Expansion: Leveraging Cytokine Modulation for Enhanced Performance
Ingegnere T; Segain B; Cozzani A; Carlsten M; Mitra S; Gaggero S
Article: MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT. 2024;32(2):101225
Endovascular transplantation of mRNA-enhanced mesenchymal stromal cells results in superior therapeutic protein expression in swine heart
Al-Saadi J; Walden M; Sandell M; Sohlmer J; Grankvist R; Friberger I; Andersson A; Carlsten M; Chien K; Lundberg J; Witman N; Holmin S
Journal article: CYTOTHERAPY. 2024;26(6):s206
DIRECT PARENCHYMAL DELIVERY TO ANY ORGAN OR TUMOR VIA NEXT GENERATION ENDOVASCULAR TECHNIQUE MINIMALLY INVASIVE AND EFFICIENT METHOD FOR TARGETED CELL AND GENE THERAPY
Al-Saadi J; Walden M; Sohlmer J; Grankvist R; Friberger I; Andersson A; Lovljung V; Settergren M; Carlsten M; Chien K; Lundberg J; Witman N; Holmin S
Article: NPJ PRECISION ONCOLOGY. 2024;8(1):108
Redirecting NK cells to the lymph nodes to augment their lymphoma-targeting capacity
Sanz-Ortega L; Leijonhufvud C; Schoutens L; Lambert M; Levy E; Andersson A; Wahlin BE; Carlsten M
Article: LEUKEMIA. 2024;38(3):579-589
Harnessing upregulated E-selectin while enhancing SDF-1α sensing redirects infused NK cells to the AML-perturbed bone marrow
Sanz-Ortega L; Andersson A; Carlsten M
Article: JOURNAL OF IMMUNOLOGY. 2024;212(5):868-880
KIR2DS1 and KIR2DL1-C245 Dominantly Repress NK Cell Degranulation Triggered by Monoclonal or Bispecific Antibodies, whereas Education by Uptuning Inhibitory Killer Ig-related Receptors Exerts No Advantage in Ab-dependent Cellular Cytotoxicity
Leijonhufvud C; Sanz-Ortega L; Schlums H; Gaballa A; Andersson A; Eriksson C; Segerberg F; Uhlin M; Bryceson YT; Carlsten M
Journal article: NUCLEAR MEDICINE AND BIOLOGY. 2023;126:108673
P-208 In vivo evaluation and optimization of [89Zr]Zr-DFO-NCS and [89Zr] Zr-(oxinate)4 for cell tracking
Friberger I; Tran T; Lu L; Milton S; Samen E; Goos J; Carlsten M; Holmin S
Article: EJNMMI RESEARCH. 2023;13(1):73
Comparative in vivo biodistribution of cells labelled with [⁸⁹Zr]Zr-(oxinate)₄ or [⁸⁹Zr]Zr-DFO-NCS using PET
Friberger I; Nilsson JNN; Lu L; Siikanen J; Ardenfors O; Milton S; Samen E; Goos JACM; Carlsten M; Holmin S; Tran TAA
Article: LEUKEMIA. 2023;37(9):1830-1841
Perturbed epigenetic transcriptional regulation in AML with IDH mutations causes increased susceptibility to NK cells
Palau A; Segerberg F; Lidschreiber M; Lidschreiber K; Naughton AJ; Needhamsen M; Jung LA; Jagodic M; Cramer P; Lehmann S; Carlsten M; Lennartsson A
Article: HAEMATOLOGICA. 2022;107(8):1786-1795
A novel CD34-specific T-cell engager efficiently depletes acute myeloid leukemia and leukemic stem cells in vitro and in vivo
Arruda LCM; Stikvoort A; Lambert M; Jin L; Rivera LS; Alves RMP; de Moura TR; Mim C; Lehmann S; Axelsson-Robertson R; Dick JE; Mattsson J; Onfelt B; Carlsten M; Uhlin M
Article: BLOOD ADVANCES. 2022;6(11):3352-3366
Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell-mediated tumor responses
Daly J; Sarkar S; Natoni A; Stark JC; Riley NM; Bertozzi CR; Carlsten M; O'Dwyer ME
Article: VIRCHOWS ARCHIV. 2022;480(3):655-666
Clinical and biological impact of SAMHD1 expression in mantle cell lymphoma
Merrien M; Wasik AM; Ljung E; Morsy MHA; Rodrigues JDM; Carlsten M; Rassidakis GZ; Christensson B; Kolstad A; Jerkeman M; Ek S; Herold N; Wahlin BE; Sander B
Article: MOLECULAR IMAGING AND BIOLOGY. 2021;23(6):952-962
Optimisation of the Synthesis and Cell Labelling Conditions for [⁸⁹Zr]Zr-oxine and [⁸⁹Zr]Zr-DFO-NCS: a Direct In Vitro Comparison in Cell Types with Distinct Therapeutic Applications
Friberger I; Jussing E; Han J; Goos JACM; Siikanen J; Kaipe H; Lambert M; Harris RA; Samen E; Carlsten M; Holmin S; Tran TA
Journal article: BRITISH JOURNAL OF HAEMATOLOGY. 2021;193(5):951-960
Combined haploidentical and cord blood transplantation for refractory severe aplastic anaemia and hypoplastic myelodysplastic syndrome.
Childs RW; Tian X; Vo P; Purev E; Kotecha RR; Carlsten M; Clara J; Flegel WA; Adams SD; Khuu HM; Stroncek DF; Cook L; Worthy T; Geller NL; Wells B; Wilder J; Reger R; Aue G
Article: BMC CANCER. 2021;21(1):500
The value of complete remission according to positron emission tomography prior to autologous stem cell transplantation in lymphoma: a population-based study showing improved outcome
Noring K; Carlsten M; Sonnevi K; Wahlin BE
Article: CLINICAL & TRANSLATIONAL IMMUNOLOGY. 2021;10(10):e1346
LIR-1 educates expanded human NK cells and defines a unique antitumor NK cell subset with potent antibody-dependent cellular cytotoxicity
Leijonhufvud C; Reger R; Segerberg F; Theorell J; Schlums H; Bryceson YT; Childs RW; Carlsten M
Journal article: METHODS IN MOLECULAR BIOLOGY. 2020;2121:213-239
CRISPR/Cas9-Based Gene Engineering of Human Natural Killer Cells: Protocols for Knockout and Readouts to Evaluate Their Efficacy.
Lambert M; Leijonhufvud C; Segerberg F; Melenhorst JJ; Carlsten M
Journal article: BLOOD. 2019;134(Supplement_1):138
Hypersialylation Protects Multiple Myeloma Cells from NK Cell-Mediated Immunosurveillance and This Can be Overcome By Targeted Desialylation Using a Sialyltransferase Inhibitor
Daly J; Sarkar S; Natoni A; Henderson R; Swan D; Carlsten M; O'Dwyer ME
Article: FRONTIERS IN IMMUNOLOGY. 2019;10:2164
Autoantibodies to Killer Cell Immunoglobulin-Like Receptors in Patients With Systemic Lupus Erythematosus Induce Natural Killer Cell Hyporesponsiveness
Segerberg F; Lundtoft C; Reid S; Hjorton K; Leonard D; Nordmark G; Carlsten M; Hagberg N
Article: FRONTIERS IN IMMUNOLOGY. 2019;10:1262
Enhanced Bone Marrow Homing of Natural Killer Cells Following mRNA Transfection With Gain-of-Function Variant CXCR4^R334X
Levy E; Reger R; Segerberg F; Lambert M; Leijonhufvud C; Baumer Y; Carlsten M; Childs R
Article: EXPERIMENTAL HEMATOLOGY & ONCOLOGY. 2019;8:7
The Karolinska experience of autologous stem-cell transplantation for lymphoma: a population-based study of all 433 patients 1994-2016
Carlsten M; Jadersten M; Hellstrom A; Littmann K; Melen CM; Junlen HR; Sonnevi K; Ljungman P; Bjorkstrand B; Wahlin BE
Article: ONCOIMMUNOLOGY. 2019;8(2):e1534664
Bortezomib sensitizes multiple myeloma to NK cells via ER-stress-induced suppression of HLA-E and upregulation of DR5
Carlsten M; Namazi A; Reger R; Levy E; Berg M; St Hilaire C; Childs RW
Article: PLOS ONE. 2018;13(8):e0202651
Body composition measurements and risk of hematological malignancies: A population-based cohort study during 20 years of follow-up
Hagstrom H; Andreasson A; Carlsson AC; Jerkeman M; Carlsten M
Article: CLINICAL CANCER RESEARCH. 2018;24(8):1834-1844
Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML
Bjorklund AT; Carlsten M; Sohlberg E; Liu LL; Clancy T; Karimi M; Cooley S; Miller JS; Klimkowska M; Schaffer M; Watz E; Wikstrom K; Blomberg P; Wahlin BE; Palma M; Hansson L; Ljungman P; Hellstrom-Lindberg E; Ljunggren H-G; Malmberg K-J
Journal article: BLOOD. 2016;128(22):2199
A Naive NK Cell Repertoire in the Circulation of Haploidentical Stem Cell Donors Pre Mobilization Predicts Rejection of Cord Myeloid Cells in Patients Undergoing Combined Haploidentical and Unrelated Cord Blood HSCT
Carlsten M; Reger RN; Kotecha R; Purev E; Tian X; Kurlander R; Aue G; Childs RW
Article: CLINICAL CANCER RESEARCH. 2016;22(21):5211-5222
Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma
Carlsten M; Korde N; Kotecha R; Reger R; Bor S; Kazandjian D; Landgren O; Childs RW
Article: FRONTIERS IN IMMUNOLOGY. 2016;7:105
Efficient mRNA-Based Genetic Engineering of Human NK Cells with High-Affinity CD16 and CCR7 Augments Rituximab-Induced ADCC against Lymphoma and Targets NK Cell Migration toward the Lymph Node-Associated Chemokine CCL19
Carlsten M; Levy E; Karambelkar A; Li L; Reger R; Berg M; Peshwa MV; Childs RW
Article: METHODS IN MOLECULAR BIOLOGY. 2016;1441:231-240
mRNA Transfection to Improve NK Cell Homing to Tumors.
Levy ER; Carlsten M; Childs RW
Journal article: BLOOD. 2015;126(23):4296
ER-Stress-Induced Suppression of HLA-E on Bortezomib-Evading Malignant Plasma Cells Dramatically Enhances Their Susceptibility to NK Cell Killing: Identification of an Achilles Heel in Myeloma Cells That Can be Utilized to Prevent Disease Relapse Following Bortezomib Treatment
Carlsten M; Namazi A; Reger RN; Berg M; Childs RW
Journal article: BLOOD. 2015;126(23):4244
Treatment of Ex Vivo Expanded NK Cells with Daratumumab F(ab')2 Fragments Protects Adoptively Transferred NK Cells from Daratumumab-Mediated Killing and Augments Daratumumab-Induced Antibody Dependent Cellular Toxicity (ADCC) of Myeloma
Cherkasova E; Espinoza L; Kotecha R; Reger RN; Berg M; Aue G; Attar RM; Sasser AK; Carlsten M; Childs RW
Journal article: BLOOD. 2015;126(23):3089
mRNA Transfection of NK Cells with Gain-of-Function CXCR4 As a Novel Method to Enhance the Homing of Adoptively Transferred NK Cells to the Bone Marrow for the Treatment of Hematological Malignancies
Levy ER; Reger RN; Carlsten M; Childs RW
Journal article: BLOOD. 2015;126(23):1894
Ex Vivo Expanded NK Cells Mediate Highly Efficient and Rapid Killing of Ewing Sarcoma Cells Through Degranulation with Tumor Cytotoxicity Controlled by the NKG2D, DNAM-1, and NKp30 NK Receptors
Karambelkar AD; Reger RN; Carlsten M; Childs RW
Article: JOURNAL OF IMMUNOLOGY. 2015;194(9):4518-4527
Coordinated Expression of DNAM-1 and LFA-1 in Educated NK Cells
Enqvist M; Ask EH; Forslund E; Carlsten M; Abrahamsen G; Beziat V; Andersson SA; Schaffer M; Spurkland A; Bryceson Y; Onfelt B; Malmberg K-J
Journal article: BLOOD CANCER JOURNAL. 2015;5(4):e306
The cellular immune system in myelomagenesis: NK cells and T cells in the development of myeloma [corrected] and their uses in immunotherapies.
Dosani T; Carlsten M; Maric I; Landgren O
Journal article: BLOOD. 2014;124(21):1120
Early and Transient Microchimerism Associated with Complete Remission after Adoptively Transferred Haploidentical NK Cells Against High Risk Myelodysplastic Syndrome and Refractory Acute Myeloid Leukemia
Bjorklund AT; Carlsten M; Schaffer M; Liu L; Cooley SA; Miller JS; Watz E; Palma M; Hansson L; Wahlin BE; Mollgard L; Hagglund H; Blomberg P; Ljungman PT; Hellstrom-Lindberg E; Ljunggren H-G; Malmberg K-J
Journal article: BLOOD. 2014;124(21):2153
Clinical-Grade mRNA Electroporation of NK Cells: A Novel and Highly Efficient Method to Genetically Reprogram Human NK Cells for Cancer Immunotherapy
Carlsten M; Li L; Su S; Berg M; Reger R; Peshwa MV; Childs R
Journal article: BLOOD. 2014;124(21):1047
A Suppressive Microenvironment in Acute Myeloid Leukemia Induces Global Alteration of T and NK Cell Profiles - Evidence for Immune-Editing Effect By Leukemia
Ito S; Barrett J; Savani BN; Jagasia M; Brissot E; Miner S; Hensel NF; Chinian F; Keyvanfar K; Battiwalla M; Savona MR; Mohan S; Carlsten M; Muranski P; Strickland SA
Article: MOLECULAR THERAPY. 2014;22(7):1388-1395
Ultra-low Dose Interleukin-2 Promotes Immune-m_odulating Function of Regulatory T Cells and Natural Killer Cells in Healthy Volunteers
Ito S; Bollard CM; Carlsten M; Melenhorst JJ; Biancotto A; Wang E; Chen J; Kotliarov Y; Cheung F; Xie Z; Marincola F; Tanimoto K; Battiwalla M; Olnes MJ; Perl S; Schum P; Hughes TE; Keyvanfar K; Hensel N; Muranski P; Young NS; Barrett AJ
Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2014;32(15_suppl):e19572
Early biomarkers of response to carfilzomib in multiple myeloma (MM): Modulation of CXCR4 and induction of autophagy.
Bhutani M; Lee M-J; Tomita Y; Lee S; Frosch A; Carlsten M; Steinberg SM; Korde N; Landgren O; Trepel JB
Article: INTERNATIONAL JOURNAL OF CANCER. 2013;133(7):1643-1652
Doxorubicin sensitizes human tumor cells to NK cell- and T-cell-mediated killing by augmented TRAIL receptor signaling.
Wennerberg E; Sarhan D; Carlsten M; Kaminskyy VO; D'Arcy P; Zhivotovsky B; Childs R; Lundqvist A
Journal article: BLOOD. 2012;120(21):3283
Ultra-Low Dose IL-2 Safely Expands Regulatory T Cells and CD56bright NK Cells in Healthy Volunteers: Towards Safer Stem Cell Donors?
Ito S; Battiwalla M; Melenhorst JJ; Carlsten M; Biancotto A; Wang E; Xie Z; Muranski P; Olnes MJ; Tanimoto K; Schum P; Perl S; Dickler H; McCoy JP; Hughes T; Bojanowski L; Hensel NF; Young NS; Barrett AJ
Journal article: BLOOD. 2011;118(21):4714
Optimizing Lentiviral Transduction of Human Natural Killer Cells
Su S; Betters DM; Ramanathan M; Keyvanfar K; Smith A; Feng X; Furutani E; Carlsten M; Lundqvist A; Childs R
Journal article: BLOOD. 2011;118(21):2944
A Phase II Trial of IPH2101 (anti-KIR mAb) in Smoldering Multiple Myeloma
Korde N; Trepel J; Carlsten M; Zingone A; Costello R; Yancey MA; Mulquin M; Maric I; Calvo K; Tembhare PR; Yuan C; Stetler-Stevenson M; Lee M-J; Alarcon S; Carter G; Childs R; Landgren O
Article: JOURNAL OF IMMUNOLOGY. 2011;187(7):3546-3554
Selenite Induces Posttranscriptional Blockade of HLA-E Expression and Sensitizes Tumor Cells to CD94/NKG2A-Positive NK Cells
Enqvist M; Nilsonne G; Hammarfjord O; Wallin RPA; Bjoerkstroem NK; Bjornstedt M; Hjerpe A; Ljunggren H-G; Dobra K; Malmberg K-J; Carlsten M
Article: LEUKEMIA. 2010;24(9):1607-1616
Reduced DNAM-1 expression on bone marrow NK cells associated with impaired killing of CD34⁺ blasts in myelodysplastic syndrome
Carlsten M; Baumann BC; Simonsson M; Jadersten M; Forsblom A-M; Hammarstedt C; Bryceson YT; Ljunggren H-G; Hellstrom-Lindberg E; Malmberg K-J
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2009;390(4):1272-1277
Regulation of interleukin-4 signaling by extracellular reduction of intramolecular disulfides
Curbo S; Gaudin R; Carlsten M; Malmberg K-J; Troye-Blomberg M; Ahlborg N; Karlsson A; Johansson M; Lundberg M
Article: JOURNAL OF IMMUNOLOGY. 2009;183(8):4921-4930
Primary Human Tumor Cells Expressing CD155 Impair Tumor Targeting by Down-Regulating DNAM-1 on NK Cells
Carlsten M; Norell H; Bryceson YT; Poschke I; Schedvins K; Liunggren H-G; Kiessling R; Malmberg K-J
Article: JOURNAL OF IMMUNOLOGY. 2008;181(9):6010-6019
Estimation of the Size of the Alloreactive NK Cell Repertoire: Studies in Individuals Homozygous for the Group A KIR Haplotype
Fauriat C; Andersson S; Bjorklund AT; Carlsten M; Schaffer M; Bjorkstrom NK; Baumann BC; Michaelsson J; Ljunggren H-G; Malmberg K-J
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2007;56(7):973-984
A short-term dietary supplementation with high doses of vitamin E increases NK cell cytolytic activity in advanced colorectal cancer patients
Hanson MGV; Ozenci V; Carlsten MCV; Glimelius BL; Frodin J-EA; Masucci G; Malmberg K-J; Kiessling RVR
Article: CANCER RESEARCH. 2007;67(3):1317-1325
DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells
Carlsten M; Bjorkstrom NK; Norell H; Bryceson Y; van Hall T; Baumann BC; Hanson M; Schedvins K; Kiessling R; Ljunggren H-G; Malmberg KJ
Article: CANCER RESEARCH. 2006;66(12):6387-6394
Frequent loss of HLA-A2 expression in metastasizing ovarian carcinomas associated with genomic haplotype loss and HLA-A2-restricted HER-2/neu-specific immunity
Norell H; Carlsten M; Ohlum T; Malmberg K-J; Masucci G; Schedvins K; Altermann W; Handke D; Atkins D; Seliger B; Kiessling R
Article: JOURNAL OF CLINICAL INVESTIGATION. 2002;110(10):1515-1523
IFN-γ protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism
Malmberg KJ; Levitsky V; Norell H; de Matos CT; Carlsten M; Schedvins K; Rabbani H; Moretta A; Söderström K; Levitskaya J; Kiessling R
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2001;276(32):30542-30551
The core promoter of human thioredoxin reductase 1
Rundlöf AK; Carlsten M; Arnér ESJ
Article: BIOCHEMICAL JOURNAL. 2000;347(Pt 3):661-668
Prominent expression of the selenoprotein thioredoxin reductase in the medullary rays of the rat kidney and thioredoxin reductase mRNA variants differing at the 5′untranslated region
Rundlöf AK; Carlsten M; Giacobini MMJ; Arnér ESJ
Visa fler

Alla övriga publikationer

Letter: HEMASPHERE. 2025;9(6):e70160
Development of myeloid neoplasia associated with prolonged immune cell-associated hematotoxicity after CAR T-cell treatment of B-cell lymphoma: Should we surveille for pre-existing myeloid mutations?
Carlsten M; Lindfors Rossi EL; Jaedersten M; Tesi B; Abd Own S; Sander B; Deneberg S; Ivinskiy A; Sonnevi K; Sjoelund H; Enblad G; Wahlin B; Mielke S
Conference publication: 2024;:a496
437 Personalized tumor-trained lymphocytes – a neoantigen targeted T cell therapy product for treatment of colorectal cancer
Gafvelin G; Joly A-L; Berglund S; Maitre EL; Urbonaviciute V; Day K; Notari L; Nilsson O; Kaiser A; Carvalho-Queiroz C; Bylund K; Woodbridge AF; Akpinar B; Jiang L; Kordes M; Carlsten M; Nikberg M; Tarfy AS; Chabok A; Salmén A; Svensson S; Xie H; Grönlund H
Conference publication: 2023;:a736
643 A first in human phase I/IIa trial of personalized tumor-trained lymphocytes, pTTL, derived from regional lymph nodes for treatment of colorectal cancer
Berglund S; Joly A-L; Maitre EL; Day K; Notari L; Carvalho-Queiroz C; Nilsson O; Kaiser A; Kordes M; Yachnin J; Carlsten M; Mielke S; Chabok A; Nikberg M; Tarfy AS; Salmén A; Svensson S; Xie H; Gafvelin G; Grönlund H
Conference publication: 2023;:a471
422 Hijacking upregulated E-selectin while boosting SDF-1α sensing rewires infused NK cells to the AML-perturbed bone marrow
Ortega LS; Andersson A; Carlsten M
Letter: HEMASPHERE. 2023;7(11):e974
Improved Leukemia Clearance After Adoptive Transfer of NK Cells Expressing the Bone Marrow Homing Receptor CXCR4^R334X
Segerberg F; Lambert M; Sanz-Ortega L; Andersson A; Childs RW; Carlsten M
Editorial comment: SIGNAL TRANSDUCTION AND TARGETED THERAPY. 2023;8(1):316
Rough operators: sphingomyelinase inhibitors spike NK cells to kill cancer
Carlsten M; Bryceson YT
Conference publication: BRITISH JOURNAL OF HAEMATOLOGY. 2023;201:114-115
Redirecting NK cells to the lymph nodes to augment their lymphoma-targeting capacity
Schoutens L; Sanz-Ortega L; Leijonhufvud C; Lambert M; Levy E; Andersson A; Wahlin B; Carlsten M
Conference publication: NUCLEAR MEDICINE AND BIOLOGY. 2023;126:S212-S213
In vivo evaluation and optimization of [⁸⁹Zr]Zr-DFO-NCS and [⁸⁹Zr] Zr-(oxinate)₄ for cell tracking
Friberger I; Thuy T; Lu L; Milton S; Samen E; Goos J; Carlsten M; Holmin S
Conference publication: BLOOD. 2022;140:8350
Comprehensive Exploration of NK Cell Education in ADCC Triggered By a Monoclonal Antibody or a Bispecific Killer Engager Molecule (BiKE)
Leijonhufvud C; Schlums H; Stikvoort A; Uhlin M; Bryceson YT; Carlsten M
Corrigendum: MOLECULAR IMAGING AND BIOLOGY. 2022;24(3):510
Optimisation of the Synthesis and Cell Labelling Conditions for [89Zr]Zr-oxine and [89Zr]Zr-DFO-NCS: a Direct In Vitro Comparison in Cell Types with Distinct Therapeutic Applications (vol 23, pg 952, 2021)
Friberger I; Jussing E; Han J; Goos JACM; Siikanen J; Kaipe H; Lambert M; Harris RA; Samen E; Carlsten M; Holmin S; Tran TA
Meeting abstract: BLOOD. 2021;138:2861
A Novel CD34-Specific T-Cell Engager Efficiently Depletes Stem Cells and Acute Myeloid Leukemia Cells in Vitro and In Vivo
Arruda LCM; Jin L; Lambert M; Rivera LS; Alvez R; de Moura TR; Mim C; Axelsson-Robertson R; Dick JE; Mattsson J; Onfelt B; Carlsten M; Uhlin M
Review: FRONTIERS IN IMMUNOLOGY. 2021;11:621225
Cytokines Orchestrating the Natural Killer-Myeloid Cell Crosstalk in the Tumor Microenvironment: Implications for Natural Killer Cell-Based Cancer Immunotherapy
Gaggero S; Witt K; Carlsten M; Mitra S
Preprint: RESEARCH SQUARE. 2020
The value of complete remission according to positron emission tomography prior to autologous stem cell transplantation in lymphoma: a population-based study showing improved outcome
Noring K; Carlsten M; Sonnevi K; Wahlin B
Review: FRONTIERS IN IMMUNOLOGY. 2019;10:2357
Natural Killer Cells in Myeloid Malignancies: Immune Surveillance, NK Cell Dysfunction, and Pharmacological Opportunities to Bolster the Endogenous NK Cells
Carlsten M; Jaras M
Conference publication: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2019;19(10):E159-E160
Hypersialylation protects Myeloma cells from NK cell mediated killing and this can be overcome by targeted desialylation using a sialyltransferase inhibitor
Daly J; Sarkar S; Natoni A; Henderson R; Swan D; Carlsten M; O'Dwyer M
Review: FRONTIERS IN IMMUNOLOGY. 2019;10:1047
Sugar Free: Novel Immunotherapeutic Approaches Targeting Siglecs and Sialic Acids to Enhance Natural Killer Cell Cytotoxicity Against Cancer
Daly J; Carlsten M; O'Dwyer M
Preprint: SSRN ELECTRONIC JOURNAL. 2018
Morbidity, Mortality and Normality after Autologous Stem-Cell Transplantation for Lymphoma: A Comprehensive, Single-Centre, Population-Based, Real-World Analysis of Patients Transplanted 1994-2016
Carlsten M; Jädersten M; Hellström A; Littmann K; Melén CM; Junlén HR; Sonnevi K; Ljungman P; Björkstrand B; Wahlin B
Conference publication: BLOOD. 2017;130
Complete Remission and Signs of Immunoediting Following Haploidentical NK Cell Therapy in Refractory High-Risk MDS and AML Ell Therapy in Refractory High-Risk MDS and AML
Bjorklund AT; Carlsten M; Sohlberg E; Clancy T; Liu L; Karimi M; Cooley S; Miller JS; Watz E; Wahlin BE; Palma M; Hansson L; Ljungman P; Hellstrom-Lindberg E; Ljunggren H-G; Malmberg K-J
Review: SEMINARS IN IMMUNOLOGY. 2017;31:20-29
Natural killer cell-mediated immunosurveillance of human cancer
Malmberg K-J; Carlsten M; Bjorklund A; Sohlberg E; Bryceson YT; Ljunggren H-G
Conference publication: BONE MARROW TRANSPLANTATION. 2016;51:S97-S98
ADOPTIVELY TRANSFERRED HAPLOIDENTICAL NK CELLS AGAINST REFRACTORY MDS, HIGH-RISK MDS AND REFRACTORY AML AS A BRIDGE TO TRANSPLANTATION. COMPLETE REMISSION ASSOCIATED WITH DETECTABLE NK CELLS
Bjorklund AT; Carlsten M; Sohlberg E; Liu L; Schaffer M; Watz E; Ljungman P; Hellstrom-Lindberg E; Ljunggren H-G; Malmberg K-J
Corrigendum: BLOOD CANCER JOURNAL. 2015;5(7):e321
The cellular immune system in myelomagenesis: NK cells and T cells in the development of MM and their uses in immunotherapies (vol 5, e306, 2015)
Dosani T; Carlsten M; Maric I; Landgren O
Review: NATURE REVIEWS DRUG DISCOVERY. 2015;14(7):487-498
Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens
Childs RW; Carlsten M
Review: FRONTIERS IN IMMUNOLOGY. 2015;6:266
Genetic manipulation of NK cells for cancer immunotherapy: techniques and clinical implications
Carlsten M; Childs RW
Meeting abstract: LEUKEMIA RESEARCH. 2015;39:S25-S26
ADOPTIVELY TRANSFERRED HAPLOIDENTICAL NK CELLS AGAINST REFRACTORY MDS, HIGH-RISK MDS AND REFRACTORY AML AS A BRIDGE TO TRANSPLANTATION. COMPLETE REMISSION ASSOCIATED WITH DETECTABLE NK CELLS
Bjorklund AT; Carlsten M; Liu L; Schaffer M; Watz E; Palma M; Hansson L; Mollgard L; Cooley SA; Miller JS; Ljungman PT; Hellstrom-Lindberg E; Ljunggren HG; Malmberg KJ
Conference publication: HLA. 2014;84(1):36
ROLE FOR DNAM-1 AS A MARKER AND EFFECTOR MOLECULE IN NATURAL KILLER CELL EDUCATION
Enqvist M; Forslund E; Ask EH; Carlsten M; Abrahamsen G; Beziat V; Andersson S; Schaffer M; Spurkland A; Bryceson Y; Onfelt B; Malmberg K-J
Conference publication: HLA. 2014;84(1):35
INTERIM REPORT OF A CLINICAL STUDY WITH HAPLOIDENTICAL NK-CELLS AGAINST HIGH RISK MDS AND AML
Bjorklund AT; Carlsten M; Liu L; Schaffer M; Watz E; Cooley S; Miller JS; Hellstrom-Lindberg E; Ljungman PT; Ljunggren H-G; Malmberg K-J
Letter: HAEMATOLOGICA. 2014;99(6):e81-e83
A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma
Korde N; Carlsten M; Lee M-J; Minter A; Tan E; Kwok M; Manasanch E; Bhutani M; Tageja N; Roschewski M; Zingone A; Costello R; Mulquin M; Zuchlinski D; Maric I; Calvo KR; Braylan R; Tembhare P; Yuan C; Stetler-Stevenson M; Trepel J; Childs R; Landgren O
Conference publication: BONE MARROW TRANSPLANTATION. 2014;49:S134-S135
INTERIM REPORT OF A CLINICAL STUDY WITH HAPLOIDENTICAL NK-CELLS AGAINST HIGH RISK MDS AND AML
Bjorklund AT; Carlsten M; Liu L; Er MS; Cooley S; Miller JS; Watz E; Wahlin B; Palma M; Hansson L; Ljungman P; Hellstrom-Lindberg E; Ljunggren H-G; Malmberg K-J
Meeting abstract: BLOOD. 2011;118(21):457-458
A Phase I Trial of Adoptively Transferred Ex-Vivo Expanded Autologous Natural Killer (NK) Cells Following Treatment with Bortezomib to Sensitize Tumors to NK Cell Cytotoxicity
Reger RN; Berg M; Lundqvist A; Donohue T; Carlsten M; Betters DM; Cook L; Ramos C; Grasmeder S; Su S; Stroncek D; Pantin J; Keyvanfar K; Carvallo CA; Khuu H; Childs R
Doctoral thesis: 2010
Molecular specificities of NK cell-mediated recognition of human tumor cells
Carlsten M
Review: INTERNATIONAL JOURNAL OF CANCER. 2009;124(4):757-762
Natural killer cell-mediated lysis of freshly isolated human tumor cells
Carlsten M; Malmberg K-J; Ljunggren H-G
Published conference paper: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2008;57(10):1541-1552
NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy
Malmberg K-J; Bryceson YT; Carlsten M; Andersson S; Bjorklund A; Bjorkstrom NK; Baumann BC; Fauriat C; Alici E; Dilber MS; Ljunggren H-G
Conference publication: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2008;68(2):223
The size of the alloreactive NK cell subset:: Implications for donor selection in allogeneic stem cell transplantation
Andersson S; Fauriat C; Bjorklund A; Carlsten M; Schaffer M; Bjorkstrom NK; Baumann BC; Ljunggren H-G; Malmberg K-J
Conference publication: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2008;68(2):185
Altered receptor repertoire and impaired function of tumor associated natural killer cells in ovarian carcinoma
Carlsten M; Norell H; Bryceson Y; Schedvins K; Ljunggren H-G; Kiessling R; Malmberg K-J
Visa fler

Anställningar

Anknuten till Forskning, Laboratoriemedicin, Karolinska Institutet, 2024-2027
Senior Forskare, Laboratoriemedicin, Karolinska Institutet, 2025-2025

Examina och utbildning

Docent, hematologi, Karolinska Institutet, 2022
Medicine Doktorsexamen, Institutionen för medicin, Huddinge, Karolinska Institutet, 2010
Läkarexamen, Karolinska Institutet, 2007

Om mig

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI